KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Deferred Revenue (2016 - 2022)

Emergent BioSolutions (EBS) has 13 years of Current Deferred Revenue data on record, last reported at $15.9 million in Q1 2022.

  • For Q1 2022, Current Deferred Revenue fell 85.9% year-over-year to $15.9 million; the TTM value through Mar 2022 reached $15.9 million, down 85.9%, while the annual FY2021 figure was $16.4 million, 83.62% down from the prior year.
  • Current Deferred Revenue reached $15.9 million in Q1 2022 per EBS's latest filing, down from $16.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $112.8 million in Q1 2021 and bottomed at $9.8 million in Q2 2018.
  • Average Current Deferred Revenue over 5 years is $70.7 million, with a median of $79.9 million recorded in 2020.
  • Peak YoY movement for Current Deferred Revenue: soared 1588.47% in 2018, then tumbled 85.9% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $73.1 million in 2018, then rose by 21.61% to $88.9 million in 2019, then increased by 12.6% to $100.1 million in 2020, then tumbled by 83.62% to $16.4 million in 2021, then decreased by 3.05% to $15.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $15.9 million in Q1 2022, $16.4 million in Q4 2021, and $82.1 million in Q3 2021.